bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2023‒12‒24
two papers selected by
Laura Mannarino, Humanitas Research
  1. Is perioperative chemotherapy effective in patients with localized myxoid liposarcoma?
  2. Rare myxoid pleomorphic liposarcoma: a case report and literature review.
  1. Jpn J Clin Oncol. 2023 Dec 21. pii: hyad179. [Epub ahead of print]
    Is perioperative chemotherapy effective in patients with localized myxoid liposarcoma?
    Tomoya Masunaga, Shinji Tsukamoto, Yuji Nitta, Kanya Honoki, Hiromasa Fujii, Manabu Akahane, Masayuki Takeda, Yasuhito Tanaka, Andreas F Mavrogenis, Costantino Errani, Akira Kawai.
      BACKGROUND: This study aimed to compare the local recurrence, distant metastasis and disease-specific survival rates of patients with localized myxoid liposarcoma in the surgery and adjuvant chemotherapy group versus the surgery alone group.METHODS: A total of 456 patients in the Japanese National Bone and Soft Tissue Tumour Registry database who had localized myxoid liposarcoma and underwent surgery and adjuvant chemotherapy or surgery alone between 2001 and 2019 were included in this retrospective study. The study adjusted for background differences between patients who underwent surgery and adjuvant chemotherapy (n = 228) or surgery alone (n = 228) using propensity score matching.
    RESULTS: Univariate analysis showed no significant difference in local recurrence rate between the two groups (5-year local recurrence-free survival: 98.6% [95% confidence interval: 95.9-99.6] vs. 94.0% [95% confidence interval: 89.7-96.6], P = 0.052). Univariate analysis showed no difference in the incidence of distant metastases between the two groups (5-year distant metastasis-free survival: 80.5% [95% confidence interval: 73.9-85.8] vs. 75.1% [95% confidence interval: 67.7-81.2], P = 0.508). Univariate analysis showed no difference in disease-specific survival between the two groups (5-year disease-specific survival: 92.6% [95% confidence interval: 86.1-96.2] vs. 93.2% [95% confidence interval: 87.6-96.4], P = 0.804). In the high-risk group (n = 203) with high-grade tumours and tumour size ≥10 cm, there were no significant differences in the local recurrence, distant metastasis and disease-specific survival rates between the surgery and adjuvant chemotherapy group and the surgery alone group.
    CONCLUSION: The effect of adjuvant chemotherapy on localized myxoid liposarcoma appears to be limited.
    Keywords:  adjuvant; chemotherapy; myxoid liposarcoma; perioperative; survival
    DOI:  https://doi.org/10.1093/jjco/hyad179
  2. J Clin Pathol. 2023 Dec 20. pii: jcp-2023-209223. [Epub ahead of print]
    Rare myxoid pleomorphic liposarcoma: a case report and literature review.
    Yanying Shen, Ling Zhao, Anqi Li, Qi Peng, Qiang Liu, Lisha Wang, Zebing Liu.
      We report a case of a middle-aged woman with a rapidly growing abdominal mass that was diagnosed as myxoid pleomorphic liposarcoma, a recently recognised, rare and aggressive subtype of liposarcoma. The tumour exhibits a combination of histological features from both myxoid liposarcoma and pleomorphic liposarcoma. Genetic analysis revealed mutations in TP53 and RB1, along with widespread loss of heterozygosity. However, no DDIT3 gene translocation or MDM2/CDK4 gene amplification was detected. These genetic characteristics can be used to distinguish this type of liposarcoma from others. Two unusual gene fusion/rearrangements, CREB5::TERT fusion and ETV1::LFNG rearrangement, were identified. The patient underwent complete removal of the tumour without the use of radiotherapy or chemotherapy. No recurrence was observed during the follow-up period of 18 months.
    Keywords:  Genes, Neoplasm; Sarcoma; Soft Tissue Neoplasms
    DOI:  https://doi.org/10.1136/jcp-2023-209223
This page is being maintained by Thomas Krichel. It was last updated on 2024‒01‒02 at 9:30.